Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer, CFF Focus On Possible Combination Approach To Treating CF’s Underlying Cause

This article was originally published in The Pink Sheet Daily

Executive Summary

Building upon CFTR-focused drugs pioneered by Vertex’s Kalydeco, Pfizer will receive up to $58 million in R&D funding from the Cystic Fibrosis Foundation to bring new CF candidates into the clinic.

You may also be interested in...

Neurofibromatosis Could Drive Cancer Indications, Advocacy Group Says

Children’s Tumor Foundation is pursuing an industry partnership model with the message that there may be drug development opportunities beyond the rare disease area.

FDA Should Create “Clearly Articulated Pathway” For Patient-Centered Research – Pfizer’s Lewis-Hall

Pfizer CMO Freda Lewis-Hall acknowledged FDA’s current activities to promote patient-centered research, but called on the agency to lead in developing guidance to help industry be more proactive in incorporating patients into its research.

Pfizer, Alliance For Lupus Research To Co-Fund Translational Projects

Pfizer’s partnership with the Alliance for Lupus Research to co-fund translational projects within the context of the pharma’s CTI program is a first. It’s a novel way to speed promising science into the clinic. But can Pfizer, a non-profit research foundation, and academic researchers reconcile their new roles and variant cultures to make the model work?

Related Content


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts